pubrio
Servier logo

Servier

Privately Held
+1
servier.com
制药制造12,700+ employeesFounded 1998🇫🇷 法国

Servier is an independent international pharmaceutical group governed by a foundation. With its unique governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle. As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. Through precision medicine, the Group intends to offer targeted therapeutic solutions for a limited number of rare diseases and invests nearly 20% of its brand-name sales in R&D. Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries. In the 2024/25 financial year, the Group achieved revenues of €6.9 billion. -- To report a suspected adverse event with a Servier drug, please visit servier.com

成立年份
1998
员工人数
12,700+
行业
制药制造
公司类型
Privately Held
总部
🇫🇷Suresnes
专长
生物技术制药制造研究与发展医疗保健及生命科学
8 / 22
活跃市场
1
新市场
BR
置信度
多为早期信号
-17%
势头
较上一周期
32 / 100
扩张评分
发展中
阶段5探索中17投入中
33 个信号 · 最近 90 天

全球扩张

实时
JPTHMX
阶段
探索中投入中进入中运营中
+19个市场已锁定
已显示 22 个中的 3 个

解锁市场时间线与信号动态

活动脉搏

最近 90 天内有 34 个信号。

最近 90 天
招聘
11-17%
招聘
营销与公关
23-8%
广告投放
产品与技术
0
无活动
+2个类别已锁定
已显示 5 个中的 3 个

市场进入时间线

该公司进入各个市场的顺序 — 从最早到最新

1
🇲🇽MX进入的第 1st 个市场 · 2023推进中
投入中
13 个信号投入中 阶段
2
🇹🇭TH进入的第 2nd 个市场 · 2024推进中
投入中
14 个信号投入中 阶段
3
🇯🇵JP进入的第 3rd 个市场 · 2025推进中
投入中
27 个信号投入中 阶段
+19个市场已锁定
已显示 22 个中的 3 个
当前阶段投入中投入资源
置信度35%
开始追踪于2023首个信号

近期信号

团队扩编🇯🇵 JP上周

13 active postings

招聘🇯🇵 JP3周前

Tibsovo Product Lead

注册以查看完整信号动态

了解一下

关于 Servier 的常见问题

关于 Servier 的业务、市场和增长信号的快速解答。

Servier is an independent international pharmaceutical group governed by a foundation. With its unique governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle. As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. Through precision medicine, the Group intends to offer targeted therapeutic solutions for a limited number of rare diseases and invests nearly 20% of its brand-name sales in R&D. Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries. In the 2024/25 financial year, the Group achieved revenues of €6.9 billion. -- To report a suspected adverse event with a Servier drug, please visit servier.com

今天就开启旅程

可以先用平台,也可以先聊聊

你可以自行使用 Pubrio,或让我们的团队协助研究、获客或数据整合。

与团队沟通
Start Journey Image
pubrio

Pubrio 将来自 50+ 本地来源的商业、人物与意向数据整合为全球图谱,帮助 AI 与营收团队洞悉全市场。

© 2026 Pubrio。保留所有权利。